Blastomycosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
(Category)
m (Bot: Removing from Primary care)
 
Line 39: Line 39:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Disease]]
{{WS}}
[[Category:Primary care]]
{{WikiDoc Help Menu}}
[[Category:Up-To-Date]]


[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Otolaryngology]]
[[Category:Otolaryngology]]
[[Category:Urology]]
[[Category:Urology]]
[[Category:Dermatology]]
[[Category:Dermatology]]
{{WS}}
[[Category:Emergency medicine]]
{{WikiDoc Help Menu}}[[Category:Emergency medicine]]
[[Category:Disease]]
[[Category:Primary care]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Dermatology]]
[[Category:Urology]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Orthopedics]]
[[Category:Orthopedics]]
[[Category:Pulmonology]]
[[Category:Pulmonology]]

Latest revision as of 20:37, 29 July 2020

Blastomycosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Blastomycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Blastomycosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Blastomycosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Blastomycosis pathophysiology

CDC on Blastomycosis pathophysiology

Blastomycosis pathophysiology in the news

Blogs on Blastomycosis pathophysiology

Directions to Hospitals Treating Blastomycosis

Risk calculators and risk factors for Blastomycosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Vidit Bhargava, M.B.B.S [2]Aditya Ganti M.B.B.S. [3]

Overview

Blastomycosis is caused by a dimorphic fungi called Blastomyces dermatitidis. It has an average incubation period of 3 weeks to 3 months after exposure. The initial neutrophilic response and the subsequent cell-mediated immune response are manifested as a suppurative tissue destruction seen in lungs, skin, and other organs. The histopathological hallmark findings on sputum microscopy is the multinucleated yeast form (budding).

Pathophysiology

Transmission

Incubation

Pathogensis

Blastomycosis - life cycle and epidemiology - Source: https://www.cdc.gov/

Dissemination

Immune response

Genetics

There is no known genetic association for blastomycosis.

Microscopic Pathology

Classic appearance on modified Wright's stain [1]

References

  1. 1.0 1.1 1.2 Saccente M, Woods GL (2010). "Clinical and laboratory update on blastomycosis". Clin. Microbiol. Rev. 23 (2): 367–81. doi:10.1128/CMR.00056-09. PMC 2863359. PMID 20375357.
  2. Smith JA, Riddell J, Kauffman CA (2013). "Cutaneous manifestations of endemic mycoses". Curr Infect Dis Rep. 15 (5): 440–9. doi:10.1007/s11908-013-0352-2. PMID 23917880.
  3. Kauffman, Carol (2011). Essentials of clinical mycology. New York: Springer. ISBN 978-1-4419-6639-1.
  4. 4.0 4.1 Koneti A, Linke MJ, Brummer E, Stevens DA (2008). "Evasion of innate immune responses: evidence for mannose binding lectin inhibition of tumor necrosis factor alpha production by macrophages in response to Blastomyces dermatitidis". Infect. Immun. 76 (3): 994–1002. doi:10.1128/IAI.01185-07. PMC 2258846. PMID 18070904.

Template:WS